David Wong,
Felix and Mildred Yip Endowed Chair in Dentistry; Director for UCLA Center for Oral/Head & Neck Oncology Research,
University of California-Los Angeles
David T.W. Wong DMD, DMSc is Felix & Mildred Yip Endowed Professor, Associate Dean of Research and Director of the Oral/Head and Neck Oncology Research Center at UCLA. Dr. Wong is an active scientist in oral cancer and saliva diagnostics research. He has authored over 280 peer reviewed scientific publications. He is a fellow of the American Association for the Advancement of Sciences (AAAS), past member of the ADA Council of Scientific Affairs and the past president of American Association of Dental Research (AADR).
Challenges in the Deployment of Saliva in Diagnostics Development
Monday, 23 March 2015 at 14:30
Add to Calendar ▼2015-03-23 09:30:002015-03-23 10:30:00Europe/LondonSaliva-based Exosomes for Liquid BiopsiesSELECTBIOenquiries@selectbiosciences.com
Extracellular RNAs (exRNAs) in biofluids have sparked considerable
interests in their use as disease-specific diagnostic and prognostic
biomarkers. In the last decade, it has been demonstrated the potential
use of salivary RNA for detecting various local and systemic diseases
such as oral cancer, Sjögren syndrome, pancreatic cancer and breast
cancer. The ability of sequence-characterized salivary exRNA by using
next-generation sequencing can further strengthen the advantages of
using saliva as a clinical diagnostic biofluid for biomarker discovery.
Compared with other bodily fluids, saliva can be collected easily and
noninvasively. However, low RNA abundance, small sample volumes, high
fragmentation of RNA and lots of bacterial contents create challenges
for downstream RNA sequencing assays.
Saliva-based Exosomes for Liquid Biopsies
Monday, 23 March 2015 at 09:30
Add to Calendar ▼2015-03-23 09:30:002015-03-23 10:30:00Europe/LondonSaliva-based Exosomes for Liquid BiopsiesSELECTBIOenquiries@selectbiosciences.com
Constitutive activation of epithelial growth factor receptor (EGFR) is
prevalent in epithelial cancers, particularly in non-small-cell lung
carcinoma (NSCLC). EGFR mutation predicts sensitivity to EGFR-targeted
therapy and mutation detection is mainly based on tissue biopsy, which
is invasive, expensive and time-consuming. Non-invasive, real-time,
point-of-care, inexpensive detection and monitoring of EGFR mutations in
NSCLC patients is highly desirable. We developed a novel core
technology, Electric Field-Induced Release and Measurement (EFIRM),
relying on a multiplexible electrochemical sensor that can detect EGFR
mutations directly from body fluids. EFIRM for EGFR mutation detection
was established in vitro, and correlated with tumor size from
xenografted mice. In clinical application, we demonstrated that EFIRM
can detect EGFR mutations from saliva and serum of 22 NSCLC patients.
And finally, a blinded test was performed on saliva from 40 NSCLC
patient saliva samples. The receiver operating characteristic analysis
indicated that EFIRM detected the exon 19 deletion with an area under
the curve (AUC) of 0.94 and the L858R mutation with an AUC of 0.96. Our
data indicate that EFIRM is effective, accurate, rapid, user-friendly,
and cost effective for the detection of EGFR mutations in saliva of
NSCLC patients. We termed this SAliva-Based EGFR (SABER) Mutation
Detection for detection and monitoring EGFR mutations in saliva of NSCLC
patients.
Add to Calendar ▼2015-03-23 00:00:002015-03-24 00:00:00Europe/LondonSample Preparation and AnalysisSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2015-03-23 09:30:002015-03-23 10:30:00Europe/LondonSaliva-based Exosomes for Liquid BiopsiesSELECTBIOenquiries@selectbiosciences.com
